INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CarMax, Inc. - KMX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 25, 2025, CarMax issued a press release reporting its financial results for the second quarter of its 2026 fiscal year.  CarMax reported earnings per share (“EPS”) of only $0.64 on $6.6 billion in sales, falling well short of consensus estimates of EPS of $1.03 on $7 billion in sales.  CarMax’s Chief Executive Officer described the quarter as “challenging” and said that the Company would cut selling, general and administrative spending by $150 million over the next 18 months. 

On this news, CarMax’s stock price fell $11.5 per share, or 20.07%, to close at $45.60 per share on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reddit, Inc. - RDDT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Reddit, Inc. (“Reddit” or the “Company”) (NYSE: RDDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Reddit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 1, 2025, RBC Capital Analyst Brad Erickson published a note, stating, in part, that “data showing declining DAU’s [daily active users] on a [trailing 30-day average] is making the rounds on social media this morning and weighing on [Reddit’s] stock, along with other third-parties flagging that Reddit’s citation share on ChatGPT has gone down significantly recently.” 

On this news, Reddit’s stock price fell $27.39 per share, or 11.91%, to close at $202.60 per share on October 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trinseo PLC - TSE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Trinseo PLC (“Trinseo” or the “Company”) (NYSE: TSE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Trinseo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Trinseo announced that it is indefinitely suspending its quarterly dividend and permanently closing its methyl methacrylate production operations in Rho, Italy, and its acetone cyanohydrin production operations in Porto Marghera, Italy.  Trinseo said that its actions are aimed at further optimizing its operations, enhancing cash flow generation and strengthening long-term profitability. 

On this news, Trinseo’s stock price fell $0.29 per share, or 12.21%, to close at $2.05 per share on October 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Braskem S.A. - BAK

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Braskem S.A. (“Braskem” or the “Company”) (NYSE: BAK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Braskem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 26, 2025, Braskem announced “that it has retained financial and legal advisors to support the Company in preparing a diagnosis of economic-financial alternatives to optimize its capital structure.” 

On this news, Braskem’s American Depositary Receipt (“ADR”) price fell $0.45 per ADR, or 14.71%, to close at $2.61 per ADR on September 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Skye and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.”  The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.” 

On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Marex Group Plc of Class Action Lawsuit and Upcoming Deadlines - MRX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Marex Group Plc (“Marex” or the “Company”) (NASDAQ: MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Marex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 8, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Marex securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 5, 2025, NINGI Research published a report entitled “Marex Group plc: A Financial House of Cards.”  In announcing the report, NINGI Research stated that, in its opinion, “Marex has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure. We have uncovered evidence suggesting Marex is a financial house of cards, with a balance sheet riddled with holes and financials that we believe are unreliable.” 

On this news, Marex’s stock price fell $2.33 per share, or 6.19%, to close at $35.31 per share on August 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in WPP Plc of Class Action Lawsuit and Upcoming Deadlines - WPP

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc (“WPP” or the “Company”) (NYSE: WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether WPP and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 8, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired WPP securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 9, 2025, WPP published a trading update for the first half of 2025, advising investors that the Company had “seen a deterioration in performance as Q2 has progressed.”  The Company attributed its misfortune to both “continued macro uncertainty weighing on client spend and weaker net new business than originally anticipated,” at least in part due to “some distraction to the business” as a result of the continued restructuring of WPP Media. 

On this news, WPP’s American Depositary Receipt (“ADR”) price fell $6.48 per ADR, or 18.09%, to close at $29.34 per ADR on July 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fortinet, Inc. of Class Action Lawsuit and Upcoming Deadlines - FTNT

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. (“Fortinet” or the “Company”) (NASDAQ: FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Fortinet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 21, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fortinet securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 6, 2025, Fortinet disclosed during its quarterly earnings call that it was already “approximately 40% to 50% of the way through the 2026 upgrade cycle” for its FortiGate firewalls – the Company’s most important product – at the end of the second quarter” of 2025.  Fortinet (i) admitted that “it’s hard[] for us to predict” the total number of FortiGates requiring an upgrade; (ii) suggested customers had “excess [firewall] capacity from [purchasing firewalls in] prior years” and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had “much business impact” as it consisted of only a “small percentage” of the Company’s business, as the age of the products at issue inherently limited the number of FortiGates eligible for an upgrade.

On this news, Fortinet’s stock price fell $21.28 per share, or 22.03%, to close at $75.30 per share on August 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RCI Hospitality Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - RICK

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (“RCI” or the “Company”) (NASDAQ: RICK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether RCI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired RCI securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 16, 2025, New York’s Office of the Attorney General announced the indictment of certain top executives of RCI, alleging that its investigation “revealed that RCI executives bribed an auditor with the New York Department of Taxation and Finance (DTF) to avoid paying over $8 million in sales taxes to New York City and the state from 2010 to 2024.” 

On this news, RCI’s stock price fell $25.80 per share, or 24.83%, over the following two trading sessions, to close at $25.80 per share on September 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors in Sina Corporation of Class Action Lawsuit and Upcoming Deadlines - SINA

NEW YORK, Pomerantz LLP announces that a securities fraud class action lawsuit has been filed against Sina Corporation (“Sina” or the “Company”) (formerly NASDAQ: SINA) and certain of its executive officers (collectively, “Defendants”) on behalf of investors who sold Sina ordinary shares, including those that sold into the Merger (defined below), between October 13, 2020 and March 22, 2021, inclusive (the “Class Period”). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Sina and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you sold Sina ordinary shares during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

This action concerns the Defendants’ fraudulent scheme to depress the value of Sina ordinary shares to avoid paying a fair price to Sina’s shareholders in connection with a take-private acquisition by a buyer group controlled by Sina’s Chief Executive Officer (the “Merger”).  Defendants executed this scheme by misrepresenting and/or omitting material information within and from Sina’s proxy materials in connection with the Merger that were necessary for shareholders to make an informed decision concerning whether to vote in favor of the Merger.  Specifically, Defendants failed to disclose that: (1) Defendants concealed the true value of the Company’s investment in TuSimple Holdings, Inc. at the time of the Merger; and (2) in turn, the offer of $43.30 per ordinary share as consideration for the Merger substantially shortchanged the true value of Sina ordinary shares. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of Class Action Lawsuit and Upcoming Deadlines - KBR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether KBR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired KBR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On June 19, 2025, HomeSafe Alliance (“HomeSafe”), a KBR joint venture, announced receipt of “a notice from the U.S. Department of Defense’s Transportation Command (TRANSCOM) terminating the Global Household Goods Contract, which HomeSafe won in 2021 to transform the military move system for the benefit of service members and their families.”  Then, on June 20, 2025, KBR issued a substantively similar press release about the termination of the Global Household Goods Contract. 

On this news, KBR’s stock price fell $3.85 per share, or 7.29%, to close at $48.93 per share on June 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

 Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quanex Building Products Corporation of Class Action Lawsuit and Upcoming Deadlines - NX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quanex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quanex securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 4, 2025, after the market closed, Quanex announced its financial results for the third quarter of its 2025 fiscal year.  Quanex disclosed, among other things, that ongoing “operational issues related to the legacy Tyman window and door hardware business in Mexico” had “impacted results more than expected[.]”  Quanex also disclosed that it was “adjusting for lower expected volumes and pushing oug the timing of when [it] expect[s] to realize procurement savings” from integration of the Tyman business.  Then, on September 5, 2025, Quanex held an earnings call to discuss the quarter’s financial results.  During the call, Chief Executive Officer George Wilson explained that the operational challenges at Tyman “negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone.”  Wilson explained that the issue had been “identified midyear” and described the systems used to “anticipate and plan for tooling repairs” as significantly deficient. 

On this news, Quanex’s stock price fell $2.73 per share, or 13.06%, to close at $18.18 per share on September 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action]  

On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for aficamten.  On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten’s NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy (“REMS”) submitted at the FDA’s request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. 

On this news, Cytokinetics’ stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025. 

Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. 

On this news, Cytokinetics’ stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in VF Corporation of Class Action Lawsuit and Upcoming Deadlines – VFC

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation (“VFC” or the “Company”) (NYSE: VFC).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether VFC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 12, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired VFC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action]  

On May 21, 2025, VFC reported its fourth quarter and full-year fiscal 2025 financial results, highlighting a significant decline in the growth trajectory for its Vans brand, which fell from an 8% loss in the previous quarter to a 20% loss in the fourth quarter.  VFC described these results and below-expectation guidance as “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses.” 

Following this news, VFC’s stock price fell $2.21 per share, or 15.8%, to close at $12.15 per share on May 21, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lantheus Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - LNTH

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations.  Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged “temporal competitive disruption.”  The Company further reduced its previous full-year projections due to Pylarify’s shortfall. 

On this news, Lantheus’s stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025. 

Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share (“EPS”) and revenue figures that missed expectations.  Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company’s full-year 2025 projections.  Lantheus attributed its results in part to ongoing competition, which impacted Pylarify’s pricing dynamics. 

On this news, Lantheus’s stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fly-E Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - FLYE

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Fly-E and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fly-E securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 14, 2025, Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues “primarily driven by a decrease in total units sold.”  In pertinent part, the Company attributed the decline to “recent lithium-battery accidents involving E-Bikes and E-Scooters.” 

On this news, Fly-E’s stock price fell $6.76 per share, or 87.11%, to close at $1.00 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Corporation of Class Action Lawsuit and Upcoming Deadlines - QMCO

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation (“Quantum” or the “Company”)(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quantum securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On June 30, 2025, Quantum disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”) that it would postpone the filing of its Annual Report because it was in the process of reviewing its revenue recognition accounting practices. 

 On this news, Quantum’s stock price fell $1.00 per share, or 10.03%, to close at $8.97 per share on July 1, 2025.  

Then, on August 8, 2025, Quantum filed a report with the SEC, announcing that the Company’s financials for the third quarter of 2024 could not be relied upon and would be restated to show a new decrease of approximately $3.9 million in revenue, and that there were deficiencies in the Company’s internal control over financial reporting and the Company’s disclosure controls and procedures that constituted material weaknesses as of December 31, 2024 and March 31, 2025.  

On this news, Quantum’s stock price fell $0.14 per share, or 1.85%, to close at $7.43 per share on August 11, 2025.  

Finally, on August 18, 2025, Quantum announced the resignation of its Chief Financial Officer Lewis Moorehead amid an internal accounting review related to its revenue recognition practices.  

On this news, Quantum’s stock price fell $0.61 per share, or 8.2%, to close at $6.83 per share on August 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tronox Holdings Plc of Class Action Lawsuit and Upcoming Deadlines - TROX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc (“Tronox” or the “Company”) (NYSE: TROX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Tronox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Tronox securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in sales of the Company’s TiO2 products for the quarter.  The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.”  As a result of the setback in sales, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60%. 

On this news, Tronox’s stock price fell $1.95 per share, or 37.94%, to close at $3.19 per share on July 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Semler securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On February 28, 2025, Semler filed its annual report for full year 2024 and disclosed that “there is a risk that [U.S. Department of Justice (‘DOJ’)] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages for tests performed using our device[.]”  The Company also revealed it had received an initial civil investigative demand from the DOJ in July 2017 regarding Semler’s claims for reimbursement related to its peripheral artery disease QuantaFlo device.  The Company further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful. 

On this news, Semler’s stock price fell $4.03 per share, or 9.4%, to close at $38.89 per share on March 3, 2025. 

Then, on April 15, 2025, Semler announced that it had reached an agreement with the DOJ “in principle on payment of $29.75 million to settle all claims.” 

On this news, Semler’s stock price fell $3.40 per share, or 9.88%, to close at $31.00 per share on April 16, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in LifeMD, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFMD

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 27, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired LifeMD securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 5, 2025, after the market closed, the Company issued a press release entitled “LifeMD Reports Second Quarter 2025 Results.”  This announcement quoted Chief Financial Officer Marc Benathen as stating that due to “some temporary challenges facing our Rex MD business,” which he claimed were “largely resolved,” that the Company was “revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics.” 

On this news, LifeMD’s stock price fell $5.31 per share, or 44.85%, to close at $6.53 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.